Phase 2 Huntington's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be a legal adult who has been diagnosed with Huntington's disease and is experiencing movement symptoms (such as involuntary movements, muscle stiffness, or slowness) and/or mental or emotional symptoms.
- You must have had a genetic test confirming a specific change in the HTT gene (a CAG repeat count of 39 or more).
- You must be able to understand and agree to participate in the study, and be able to attend the scheduled visits.
- If you are a woman who could become pregnant, you must have a negative pregnancy test at the start of the study and agree to use contraception throughout the trial.
- If you are a man whose partner could become pregnant, you must agree to use contraception throughout the trial.
Who may not be able to join:
- People who have other serious health conditions that the study doctors consider medically significant.
- People who are pregnant or currently breastfeeding.
- People whose Huntington's disease has progressed to the point where they need help with basic daily activities, or who have severe memory or thinking difficulties (confirm with trial site).
- People who are currently experiencing active psychosis (such as hallucinations or delusions) at the time of screening.
- People with severe kidney failure.
- People who have previously been treated with thiamine and/or biotin, or who are enrolled in another Huntington's disease trial involving a specific type of drug called an antisense oligonucleotide (IONIS-HTTRX/RG6042).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pablo Mir Rivera, MD/PhD, Institute of Biomedicine of Seville (IBiS)
Phone: +34 955923039
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-Emergent Adverse Events as assessed by clinical examination anamnesis and Analytical monitoring with hematological and biochemical control (hepatic and renal function)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.